In type-2 diabetes patients, NLRP3 inflammasome activation is higher in myeloid cells, and NLRP3 inflammasome inhibitors might be clinically useful in treating ischemic stroke concomitant with diabetes (126, 174). Here, NLRP3 is linked to ischemic stroke.